TrialThe journal of headache and pain2019

Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.

Robert E Shapiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.